EP2386560A1 - Hydrate de naphthalenesulfonate de clopidogrel cristallin, son procédé de préparation et composition pharmaceutique le contenant - Google Patents

Hydrate de naphthalenesulfonate de clopidogrel cristallin, son procédé de préparation et composition pharmaceutique le contenant Download PDF

Info

Publication number
EP2386560A1
EP2386560A1 EP11005458A EP11005458A EP2386560A1 EP 2386560 A1 EP2386560 A1 EP 2386560A1 EP 11005458 A EP11005458 A EP 11005458A EP 11005458 A EP11005458 A EP 11005458A EP 2386560 A1 EP2386560 A1 EP 2386560A1
Authority
EP
European Patent Office
Prior art keywords
clopidogrel
formula
naphthalenesulfonate
monohydrate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11005458A
Other languages
German (de)
English (en)
Inventor
Sangmin Yun
Eun Sook Kim
Hee-Seock Kim
Bo Sung Kwon
Cheol Kyung Kim
Han Kyong Kim
Kwee-Hyun Suh
Gwan Sun Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020040041309A external-priority patent/KR100563455B1/ko
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of EP2386560A1 publication Critical patent/EP2386560A1/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to crystalline clopidogrel naphthalenesulfonate or hydrate thereof, a method for preparing same, and a pharmaceutical composition containing same.
  • Clopidogrel (methyl (+)-(S)- ⁇ -( o -chlorophenyl)-6,7-dihydrothieno[3,2-a]pyridine-5(4 H )-acetate), the compound of formula (II) is known as a useful medicament for the treatment and prevention of various platelet-associated vascular diseases such as stroke, cerebral arteriosclerosis, myocardial infarction, angina pectoris, arrhythmia, peripheral arteries disease, and Burger's disease ( see European Patent No. 281,459 B1 and U.S. Patent No. 4,847,265 ).
  • clopidogrel itself as free base form is an oil which is difficult to purify, and the ester group thereof liable to hydrolysis to produce the acid of formula (III) which has no biological activity. Also, under moist and heat conditions, it can be transformed to the levorotatory isomer of formula (IV) having much less pharmacological activity. Accordingly, there has been a need to convert clopidogrel to a crystalline form which is very stable and easily purifiable, and for the purpose, it is common to make an acid addition salt using a pharmaceutically acceptable inorganic or organic acid.
  • European Patent No. 281,459 B1 and U.S. Patent No. 4,847,265 disclose a number of acid addition salts of clopidogrel prepared using various inorganic or organic acids. However, it is described that most of these salts are amorphous, hygroscopic and/or low melting, which are improper to use in pharmaceutical composition. Even the claimed crystalline salts such as hydrochloride, hydrobromide, hydrogen sulfate, and taurocholate, have some problems. The taurocholate is unsuitable for use as a pharmaceutically acid addition salt of clopidogrel because taurocholic acid itself has another pharmacological activity, i.e., bile secretion. Also it was confirmed by the inventors that the hydrochloride and hydrobromide salts are highly hygroscopic under a condition of 60°C temperature and 75% relative humidity, resulting in gum type or liquefied form.
  • PLAVIX R Sanofi-Synthelabo Inc.
  • PLAVIX R clopidogrel hydrogen sulfate
  • European Patent No. 281,459 B1 and U.S. Patent No. 6,429,210 clopidogrel hydrogen sulfate
  • H. Agrawal et al, Talanta, 61: 581-589, 2003 it was reported PLAVIX R is unstable under an accelerated test condition (40 °C , 75% relative humidity, for 3 months), producing significant amounts of impurities (see Y. Gomez et al, J. Pharm. Biomed. Anal. 34: 341-348, 2004 ).
  • clopidogrel hydrogen sulfate has two polymorphic forms which differ from each other in terms of physicochemical properties, and one of the two forms can be contaminated into the other during its manufacture varying from batch to batch. This makes it difficult to maintain a pharmaceutically required homogeneous polymorphic state.
  • a pharmaceutical composition comprising same is effective for the prevention or treatment of platelet-associated vascular diseases.
  • a method for preparing a crystalline clopidogrel naphthalenesulfonate of formula (I) or a hydrate thereof which comprises: reacting a clopidogrel free base of formula (II) with a naphthalenesulfonic acid of formula (V) or a hydrate thereof (H + ) n X n- (V) in an organic solvent, wherein X is naphthalenemonosulfonate when n is 1 or naphthalenedisulfonate when n is 2.
  • a pharmaceutical composition containing the crystalline clopidogrel naphthalenesulfonate or the hydrate thereof, for the prevention or treatment of the platelet-associated vascular disease.
  • the crystalline clopidogrel naphthalenesulfonate of formula (I) is a novel salt of clopidogrel, which is less hygroscopic, thermostable, and can be prepared in a much more optically pure form than any of the conventional salts.
  • the naphthalenesulfonate group (X) of the crystalline clopidogrel naphthalenesulfonate of formula (I) or the hydrate thereof is derived from 2-naphthalenesulfonic acid, 3-naphthalenesulfonic acid, 1,2-naphthalenedisulfonic acid, 1,3-naphthalenedisulfonic acid, 1,4-naphthalenedisulfonic acid, 1,5-naphthalenedisulfonic acid, 1,6-naphthalenedisulfonic acid, 1,7-naphthalenedisulfonic acid, 1,8-naphthalenedisulfonic acid, 2,3-naphthalenedisulfonic acid, 2,6-naphthalenedisulfonic acid or 2,7-naphthalenedisulfonic acid; and clopidogrel 2-naphthalenesulfonate of formula (Ia) (napsilate according to INN), clopidogrel 1,5-n
  • the clopidogrel naphthalenesulfonate of formula (I) forms a crystalline structure as an anhydrous or hydrous form thereof.
  • the clopidogrel naphthalenesulfonate of formula (Ia) can be crystallized in the anhydrous form whose powder X-ray diffraction (XRD) scan shows major peaks having I/I 0 values greater than 10% (100 ⁇ I/I 0 >10) at 2theta (2 ⁇ ) of 6.7, 8.2, 8.5, 12.4, 13.0, 13.5, 16.8, 17.2, 18.9, 19.6, 20.2, 21.2, 22.3, 22.9, 23.2, 23.6, 24.7, 25.0, 25.3, 25.8, 27.0, 27.5, 28.0, 28.6, 32.1, 32.5, and 34.7 ( Fig. 1 ).
  • XRD powder X-ray diffraction
  • Differential scanning calorimeter (DSC) curve of the clopidogrel 2-naphthalenesulfonate at 10°C/min shows an absorption peak of about 55.3 J/g whose heat absorption is started at about 146.7°C and maximized at about 150.9°C ( Fig. 2 ).
  • the actually observed melting point of clopidogrel 2-naphthalenesulfonate is 150 to 151 °C.
  • the clopidogrel 1,5-naphthalenedisulfonate of formula (Ib) crystallizes as a monohydrate whose powder XRD scan shows major peaks having I/I 0 values greater than 10% (100 ⁇ I/I 0 >10) at 2 ⁇ of 7.6, 9.7, 10.7, 11.0, 12.1, 13.6, 14.2, 15.3, 16.6, 17.0, 18.1, 18.5, 19.8, 21.5, 22.2, 23.0, 23.5, 24.3, 24.8, 25.7, 26.4, 26.9, 27.3, 28.4, and 29.0 ( Fig. 3 ).
  • DSC curve of such clopidogrel 1,5-naphthalenedisulfonate at 5°C/min shows an absorption peak of about 158.3 J/g whose heat absorption is started at about 219.3°C and maximized about 226.4°C ( Fig. 4 ).
  • the actually observed melting point of clopidogrel 1,5-naphthalenedisulfonate is 223 to 225 °C .
  • the clopidogrel naphthalenesulfonate of formula (I) may be prepared by reacting clopidogrel free base with naphthalenemonosulfonic acid, naphthalenedisulfonic acid or a hydrate thereof in an organic solvent.
  • the clopidogrel naphthalenesulfonate of formula (I) is prepared by reacting clopidogrel free base of formula (II) with naphthalenesulfonic acid of formula (V) or a hydrate thereof in an organic solvent having no adverse effect on the salt formation, to obtain a crystalline product, followed by isolating the crystalline product.
  • the organic solvent which may be used in the present invention includes at least one solvent selected from the group consisting of methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, acetone, methyl ethyl ketone, methyl isobutyl ketone, acetonitrile, methanol, tetrahydrofuran, 1,4-dioxane and a mixture thereof; ethyl acetate, acetone and methanol being most preferred.
  • the organic solvent may contain water up to 15 v/v%.
  • the organic solvent may be employed in an amount ranging from 1 to 20 by ml volume, preferably 3 to 10 by ml volume, bas ed on 1g weight of the clopidogrel free base.
  • naphthalenesulfonic acid or a hydrate thereof may be employed in an amount ranging from 1.0 to 1.2 moles based on 1.0 mole of the clopidogrel free base.
  • the reaction may be performed at a temperature ranging from -10°C to the boiling point of the solvent.
  • the reaction is preferably performed at a temperature ranging from 15 to 45 °C for a period ranging from 1 to 24 hours after the addition of naphthalenesulfonic acid or a hydrate thereof to the mixture, followed by cooling and stirring the mixture at a temperature ranging from -10 to 10°C for a period ranging from 1 to 24 hours after precipitation formation.
  • the precipitates thus formed may be filtered under a reduced pressure, and washed with a suitable solvent.
  • the precipitates are dried using an inert gas such as air and nitrogen under an atmospheric pressure or under a reduced pressure at a temperature ranging from 40 to 70°C.
  • the clopidogrel free base of formula (II) used as a starting material in the present invention may be prepared according to the known method disclosed in International Patent Publication No. WO 02/59128 .
  • naphthalenesulfonic acid is nontoxic (for example, LD 50 of 2-naphthalenesulfonic acid is 4,440 mg/kg and sodium salt thereof is 13,900 mg/kg; and that of 1,5-naphthalenedisulfonic acid is 2,420 mg/kg, when they are orally administered to rat; see GISAAA, 39(1), 101, 1974 ), it can be safely employed in the preparation of acid addition salts for a drug (see S. M. Berge et al, J. Pharm. Sci. 66: 1, 1977 ).
  • the crystalline clopidogrel naphthalenesulfonate of formula (I) prepared by the above method is non-hygroscopic, stable against moisture and heat, and optically pure.
  • the platelet-associated vascular disease selected from the group consisting of stroke, cerebral arteriosclerosis, myocardial infarction, angina pectoris, arrhythmia, peripheral arteries disease, and Burger's disease.
  • a pharmaceutical composition comprising the inventive clopidogrel naphthalenesulfonate as an active ingredient may be administered via the oral route, and, thus, the pharmaceutical composition of the present invention may be in the form of solutions, suspensions, tablets, pills, capsules, powders, and the like.
  • composition according to the present invention may be formulated together with pharmaceutically acceptable carriers, diluents, or excipients, if necessary.
  • suitable carriers, diluents, or excipients are excipients such as starch, sugar and mannitol; filling agents or increasing agents such as calcium phosphate and silica derivatives; binding agents such as cellulose derivatives of carboxymethylcellulose or hydroxypropylcellulose, gelatin, arginic acid salt, and polyvinylpyrrolidone; lubricating agents such as talc, magnesium or calcium stearate, hydrogenated castor oil and solid polyethylene glycol; disintegrants such as povidone, croscarmellose sodium, and crospovidone; and surfactants such as polysorbate, cetyl alcohol and glycerol monostearate.
  • excipients such as starch, sugar and mannitol
  • filling agents or increasing agents such as calcium phosphate and silica derivatives
  • binding agents such as cellulose derivatives of carboxymethylcellulose or hydroxypropylcellulose, gelatin, arginic acid salt, and polyvinylpyrrolidon
  • compositions comprising a specific amount of active ingredient, together with or without additives such as said excipients, diluents or additives, may be prepared in accordance with any of the conventional procedures (see Remington's Pharmaceutical Science, Mack Publishing Company, Easton, PA, 19th Edition, 1995 ).
  • the pharmaceutical composition according to the present invention may contain the clopidogrel naphthalenesulfonate or the hydrate thereof in an amount ranging from 0.1 to 95% by weight, preferably 1 to 70% by weight based on the total composition weight.
  • the clopidogrel naphthalenesulfonate of formula (I) according to the present invention may be orally administered to a subject in a dose ranging from 1 to 1000 mg/60 kg weight, preferably 25 to 250 mg/60 kg weight per day.
  • Condition B For the measurement of an amount of hydrolyzed impurities of an acid addition salt of clopidogrel
  • Clopidogrel hydrogen sulfate as a crystalline form 2 was prepared according to the method disclosed in U.S. Patent No. 6,429,210 from clopidogrel free base having an optical purity of 99.3 %ee which had been prepared by the method disclosed in International Patent Publication No. WO 02/59128 . m.p.: 176 ⁇ 177°C; water (Karl-Fisher titrator): below 0.1%; assay (HPLC, condition A): 99.94%; and optical purity (HPLC, condition C): 99.3 %ee
  • clopidogrel free base having an optical purity of 99.3 %ee which was prepared by the method similar to that disclosed in International Patent Publication No. WO 02/59128 was dissolved in 100ml of ethyl acetate, and a solution containing 34.8g of 2-naphthalenesulfonic acid monohydrate dissolved in a mixture of 150ml of ethyl acetate and 5ml of water was added thereto dropwise over a period of 30 minutes. Then, the mixture was stirred at room temperature for 12 hours, and then, at a temperature ranging from 0 to 5 for 4 hours.
  • clopidogrel free base having an optical purity of 99.3 %ee prepared by the method similar to that disclosed in International Patent Publication No. WO 02/59128 was dissolved in 300ml of acetone, and a solution containing 28.9g of 1,5-naphthalenedisulfonic acid tetrahydrate dissolved in a mixture of 290ml of acetone and 10ml of water was added thereto dropwise over a period of 30 minutes. Then, the mixture was stirred at room temperature for 12 hours, and then, at a temperature ranging from 0 to 5°C for 4 hours.
  • Example 3 Stability test of acid addition salts of clopidogrel under moist and heated condition
  • the assay of the acid addition salt of clopidogrel was measured using HPLC condition A, the amount of hydrolyzed impurities of the acid addition salt of clopidogrel was measured using HPLC condition B, the optical purity of the acid addition salt of clopidogrel (i.e., the amount of the levorotatory isomers) was measured using the HPLC condition C, and the water content of the acid addition salt of clopidogrel was measured with a Karl-Fisher titrator. The results are shown in Tables 3 to 6 and Figs. 5 to 8 , respectively.
  • the inventive clopidogrel naphthalenesulfonate is less hygroscopic, and more stable against moisture and heat
  • there was no significant decline in the amount of optically pure clopidogrel after storage under a severe condition for a long period and hydrolyzed impurities of the clopidogrel naphthalenesulfonate were far less in amount than that observed for hydrogen sulfate.
  • the optical purities of the acid addition salts then obtained were measured under HPLC condition C, and the extents of optical purity improvement are shown in Table 7.
  • Clopidogrel is liable to be partially racemized to its levorotatory isomer, and thus, a plurality of purification steps is required to achieve a pharmaceutically acceptable optical purity.
  • the inventive method of preparing the naphthalenesulfonate provides a product which meets the pharmaceutical optical purity requirements, so that separate optical purification steps can be omitted.
  • the platelet aggregation inhibition test was performed ex vivo, and the inhibitory activities of the acid addition salts against platelets aggregation induced by adenosine-diphosphate (ADP), collagen and thrombin, respectively, were measured.
  • ADP adenosine-diphosphate
  • Blood samples were taken using a syringe pre-charged with 3.8% citric acid solution from the abdominal artery of the animals under anesthesia, and the blood samples were centrifuged at 4°C and 1,000 rpm for 10 minutes to separate platelet-rich plasma (PRP). The separated plasma was further centrifuged four times at 4°C and 1,000 rpm to obtain PRP for test.
  • PRP platelet-rich plasma
  • a portion of PRP was further centrifuged at 4 °C and 3,000 rpm for 10 minutes to prepare precipitated platelet, and the precipitated platelet was washed with a buffer (138 mM NaCl, 2.7 mM KCI, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 5.5 mM glucose, 1 mM EDTA: pH 6.5).
  • the platelet was suspended in a buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 0.49 mM MgCl 2 , 0.25% gelatin, 5.5 mM glucose: pH 7.4) such that the optical density (OD) value at 260nm corresponded to a number of platelet which is about 1 ⁇ 10 8 .
  • a buffer 138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.36 mM NaH 2 PO 4 , 0.49 mM MgCl 2 , 0.25% gelatin, 5.5 mM glucose: pH 7.4
  • ADP standard solution was added to the above PRP to determine the concentration until the final concentration of the ADP became 5 ⁇ M. Further, a collagen standard solution (final concentration 5 ⁇ g/ml) and thrombin standard solution (final concentration 0.1 U/ml) was added to the above washing platelet solution to induce platelet aggregation. Each of the samples was stirred at 37°C and 900 rpm to measure the amount of platelet aggregation using a aggregometer (Chrono-log Platelet Aggregometer). The degrees of platelet aggregation and inhibition were calculated using formulae 1 and 2, and the results are shown in Table 8.
  • Sprague-Dawley rats Forty 11 to 12-weeks old male and female Sprague-Dawley rats (average weight: 270 ⁇ 25g) were divided into four groups each consisting of five male rats and five female rats, and the male rats of the first group were each orally administered with 5.0mg/kg of clopidogrel hydrogen sulfate (3.83mg/kg as clopidogrel) and the female rats of the first group were each orally administered with 2.5mg/kg (1.92mg/kg as clopidogrel).
  • the male and female rats were orally each administered with 6.30mg/kg and 3.15mg/kg of clopidogrel 2-naphthalenesulfonate, respectively, and for the third group, the male and female rats were each orally administered with 5.65mg/kg and 2.83mg/kg of clopidogrel 1,5-naphthalenedisulfonate monohydrate, respectively.
  • the drug was orally administered in the form of 1% DMSO solution in an amount in volume of 10 ml/kg body weight. As a comparison, only 1% DMSO solution was administered to the last group of rats.
  • the tail of the rat was pierced at a position of 1.5cm from the end of tail using a need of 26G ⁇ 1/2 , 0.45 ⁇ 13mm at a depth of 1mm.
  • the time of bleeding to cease was measured with absorbing the bleeding blood on a filter paper every 10 second. The result is shown in Table 9.
  • the inventive clopidogrel naphthalenesulfonate inhibits the platelet aggregation induced by ADP, collagen or thrombin, and significantly extends the bleeding time as compared with the conventional acid addition salts, e.g., hydrogen sulfate. Therefore, the clopidogrel naphthalenesulfonate according to the present invention is more effective than any of the conventional acid addition salts in the prevention or treatment for platelet-associated vascular diseases.
  • the clopidogrel naphthalenesulfonate of the present invention may be formulated alone or in a combination with pharmaceutically acceptable additives, according to any of the conventional methods used to prepare soft or hard capsules and tablets.
  • a gelatin capsule was prepared using the following ingredients: Quantity(mg/capsule) Clopidogrel 2-naphthalenesulfonate 120 Lactose 100 Corn starch 25 Silicon dioxide colloid 3 Magnesium stearate 2 Total 250
  • a gelatin capsule was prepared using the following ingredients: Quantity(mg/capsule) Clopidogrel 1,5-naphthalenedisulfonate monohydrate 110 Lactose 110 Corn starch 25 Silicon dioxide colloid 3 Magnesium stearate 2 Total 250
  • a tablet was prepared using the following ingredients: Quantity(mg/tablet) Clopidogrel 2-naphthalenesulfonate 120 Anhydrous lactose 90 Microcrystalline cellulose 30 Hydroxypropylcellulose 5 Polysorbate 2 Hydrogenated castor oil 1 Magnesium stearate 1 Solid polyethylene glycol 1 Total 250
  • a tablet was prepared using the following ingredients: Quantity (mg/tablet) Clopidogrel 1,5-naphthalenedisulfonate monohydrate 110 Anhydrous lactose 100 Microcrystalline cellulose 30 Hydroxypropylcellulose 5 Polysorbate 2 Hydrogenated castor oil 1 Magnesium stearate 1 Solid polyethylene glycol 1 Total 250
  • the clopidogrel naphthalenesulfonate according to the present invention easily meets the optical purity requested by the pharmaceutical formulation simply by carrying out the inventive process.
  • the clopidogrel naphthalenesulfonate is very stable against moisture and heat, so that a high purity of active ingredient can be maintained for a prolonged time.
  • the clopidogrel naphthalenesulfonate is better than the conventional salts in terms of pharmaceutical effects in animal experiments using rats. Accordingly, the clopidogrel naphthalenesulfonate according to the present invention is more useful than any of the conventional acid addition salts in the prevention or treatment for the platelet-associated vascular disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EP11005458A 2004-04-09 2004-10-18 Hydrate de naphthalenesulfonate de clopidogrel cristallin, son procédé de préparation et composition pharmaceutique le contenant Withdrawn EP2386560A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20040024361 2004-04-09
KR1020040041309A KR100563455B1 (ko) 2004-04-09 2004-06-07 결정성 클로피도그렐 나프탈렌술폰산염 또는 이의 수화물,이의 제조방법 및 이를 함유하는 약학적 조성물
EP04793523A EP1732932B1 (fr) 2004-04-09 2004-10-18 Naphthalenesulfonate cristallin de clopidogrel ou hydrate de celui-ci, procede permettant de le preparer et composition pharmaceutique le contenant

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP04793523.4 Division 2004-10-18

Publications (1)

Publication Number Publication Date
EP2386560A1 true EP2386560A1 (fr) 2011-11-16

Family

ID=35061381

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11005458A Withdrawn EP2386560A1 (fr) 2004-04-09 2004-10-18 Hydrate de naphthalenesulfonate de clopidogrel cristallin, son procédé de préparation et composition pharmaceutique le contenant
EP04793523A Not-in-force EP1732932B1 (fr) 2004-04-09 2004-10-18 Naphthalenesulfonate cristallin de clopidogrel ou hydrate de celui-ci, procede permettant de le preparer et composition pharmaceutique le contenant

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04793523A Not-in-force EP1732932B1 (fr) 2004-04-09 2004-10-18 Naphthalenesulfonate cristallin de clopidogrel ou hydrate de celui-ci, procede permettant de le preparer et composition pharmaceutique le contenant

Country Status (13)

Country Link
US (1) US7470707B2 (fr)
EP (2) EP2386560A1 (fr)
JP (1) JP4550884B2 (fr)
CN (1) CN1938319B (fr)
AU (1) AU2004318214B2 (fr)
BR (1) BRPI0418726A (fr)
CA (1) CA2562532C (fr)
HK (1) HK1098482A1 (fr)
IL (1) IL177806A0 (fr)
NO (1) NO20065144L (fr)
NZ (1) NZ551153A (fr)
RU (1) RU2328501C1 (fr)
WO (1) WO2005097804A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680430B1 (fr) * 2003-11-03 2010-01-20 Cadila Healthcare Ltd. Procedes de preparation de forme i de (s)-(+)- clopidogrel bisulfate
GB0418580D0 (en) * 2004-08-21 2004-09-22 Ivax Pharmaceuticals Sro Clopidogrel salt
IS2385B (is) * 2006-02-10 2008-07-15 Actavis Group Hf. Klópidógrel bísúlfat lyfjasamsetningar
KR100945062B1 (ko) 2006-03-22 2010-03-05 한미약품 주식회사 클로피도그렐 1,5-나프탈렌디술폰산염 및 이의 수화물의제조방법
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
KR20160033792A (ko) 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
EP2107061A1 (fr) 2008-04-02 2009-10-07 Krka Tovarna Zdravil, D.D., Novo Mesto Procédé de préparation de clopidogrel enrichi optiquement
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EP2578570A1 (fr) 2011-10-07 2013-04-10 Almirall, S.A. Nouveau procédé de fabrication de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy)hexyl]amino}-1-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one via de nouveaux intermédiaires de synthèse
EP2641900A1 (fr) 2012-03-20 2013-09-25 Almirall, S.A. Nouvelles formes polymorphes de héminapadisylate de 5-(2-{[6-(2,2-difluoro-2-phényléthoxy) hexyl]amino}-1-(R)-hydroxyéthyl)-8-hydroxyquinolin-2(1h)-one en tant qu'agoniste du récepteur adrénergique ß2
CN111620795B (zh) * 2020-04-27 2021-11-19 华东师范大学 芳基、烷基磺酸类化合物及采用无机硫盐的构建方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847265A (en) 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
WO2002059128A2 (fr) 2001-01-24 2002-08-01 Cadila Healthcare Ltd. Procede de preparation de clopidogrel
US6429210B1 (en) 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
WO2005103059A1 (fr) * 2004-04-20 2005-11-03 Sanofi-Aventis Sel de clopidogrel et formes polymorphes associees

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2815691B2 (ja) * 1990-09-20 1998-10-27 麒麟麦酒株式会社 Ｋｒｎ２３９１酸付加塩およびその用途
US6133244A (en) * 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
ES2316650T3 (es) * 2001-12-18 2009-04-16 Teva Pharmaceutical Industries Ltd. Polimorfos de hidrogenosulfato de clopidogrel.
HUP0200438A3 (en) * 2002-02-06 2003-10-28 Egis Gyogyszergyar Nyilvanosan Novel clopidogrel hydrochloride polymorphs, process for the preparation thereof, their use and pharmaceutical compositions containing them
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
CZ297472B6 (cs) * 2002-08-27 2006-12-13 Zentiva, A.S. Zpusob výroby clopidogrelu hydrogensulfátu krystalické formy I
GB2393181A (en) * 2002-09-19 2004-03-24 Cipla Ltd Amorphous clopidogrel
DE10305984A1 (de) * 2003-02-13 2004-09-02 Helm Ag Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen
JP2007523203A (ja) * 2004-02-24 2007-08-16 ジークフリート・ジェネリクス・インターナショナル・アクチェンゲゼルシャフト クロピドグレルの薬理学的に許容できる塩

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847265A (en) 1987-02-17 1989-07-11 Sanofi Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) thieno pyridyl) (2-chlorophenyl)-acetate and the pharmaceutical compositions containing it
EP0281459B1 (fr) 1987-02-17 1995-04-26 Sanofi Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant
US6429210B1 (en) 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
WO2002059128A2 (fr) 2001-01-24 2002-08-01 Cadila Healthcare Ltd. Procede de preparation de clopidogrel
WO2005103059A1 (fr) * 2004-04-20 2005-11-03 Sanofi-Aventis Sel de clopidogrel et formes polymorphes associees

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Science", 1995, MACK PUBLISHING COMPANY
BORN G.V.R, CROSS, J. PHYSIOL., vol. 168, 1963, pages 178 - 195
DEJANA E, VILLA S, THROMB. HAEMOSTAS, vol. 48, 1982, pages 108 - 111
GISAAA, vol. 39, no. 1, 1974, pages 101
H. AGRAWAL ET AL., TALANTA, vol. 61, 2003, pages 581 - 589
O. TAKAHASHI, FOOD & CHEMICAL TOXICOLOGY, vol. 38, 2000, pages 203 - 218
S. M. BERGE ET AL., J. PHARM. SCI., vol. 66, no. 1, 1977
Y. GOMEZ ET AL., J. PHARM. BIOMED. ANAL., vol. 34, 2004, pages 341 - 348

Also Published As

Publication number Publication date
EP1732932A1 (fr) 2006-12-20
JP2007532530A (ja) 2007-11-15
RU2328501C1 (ru) 2008-07-10
EP1732932A4 (fr) 2010-04-21
CA2562532C (fr) 2010-02-16
CA2562532A1 (fr) 2005-10-20
EP1732932B1 (fr) 2012-03-21
IL177806A0 (en) 2006-12-31
CN1938319A (zh) 2007-03-28
WO2005097804A1 (fr) 2005-10-20
US7470707B2 (en) 2008-12-30
AU2004318214B2 (en) 2007-12-06
US20050228012A1 (en) 2005-10-13
BRPI0418726A (pt) 2007-09-11
AU2004318214A1 (en) 2005-10-20
CN1938319B (zh) 2010-05-12
HK1098482A1 (en) 2007-07-20
NO20065144L (no) 2007-01-08
NZ551153A (en) 2009-10-30
JP4550884B2 (ja) 2010-09-22

Similar Documents

Publication Publication Date Title
EP2112155B1 (fr) Sel hydrogénosulfate de 2-acétoxy-5-(a-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tétrahydrothiéno[3,2-c]pyridine et sa préparation
JP2008509953A (ja) ４−［［（７ｒ）−８−シクロペンチル−７−エチル−５，６，７，８−テトラヒドロ−５−メチル−４−６−オキソ−２−ピペリジニル］アミノ］−３−メトキシ−ｎ−（１−メチル−４−ピペリジニル）ベンズアミドの水和物及び多形、その製造方法、並びにその薬物としての使用
KR20070052780A (ko) 결정질 클로피도그렐 브롬산염 및 이의 제조 방법
EP1732932B1 (fr) Naphthalenesulfonate cristallin de clopidogrel ou hydrate de celui-ci, procede permettant de le preparer et composition pharmaceutique le contenant
EP1309556B1 (fr) Fumarate d'amlodipine
KR100878698B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및이를 포함하는 약학 조성물
CA2433190C (fr) Amlodipine hemimaleate
IL167659A (en) Crystalline sibutramine methanesulfonate hemihydrate, pharmaceutical compositions containing the same and methods for the preparation thereof
AU2003251974B2 (en) Novel salt and polymorphs of desloratadine hemifumarate
ZA200609248B (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutica composition containing same
US7335380B2 (en) Amlodipine free base
AU2007227919B2 (en) Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof
KR19990007796A (ko) 혈관 신생 억제제
MXPA06011131A (en) Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
KR101307712B1 (ko) 결정형의 베포타스틴 금속염 수화물, 이의 제조방법 및 이를 포함하는 약학 조성물
KR100742134B1 (ko) 결정성Ｓ-(+)-메틸-2-(2-클로로페닐)-2-(6,7-디히드로티에노[3,2-ｃ]피리딘-5(4Ｈ)-일)아세테이트·캄실레이트를 포함하는약학적 조성물
AU2001100436A4 (en) Amlodipine hemimaleate
AU2001100435A4 (en) Amlodipine fumarate
AU2001100438A4 (en) Aspartate derivative of amlodipine
KR20080003601A (ko) 피롤로피리미디논 유도체의 시트레이트 염 및 이의제조방법
SI21066A2 (sl) Amlodipin fumarat

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 1732932

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120517